Jun 22, 2026 | Acquisition Cost Index (ACI) pricing, MedBen Rx, Pharmacy Benefits Manager (PBM), Rebates, Spread Pricing
MedBen Rx is the fastest growing division of MedBen — and for good reason. Here’s how we stack up against traditional PBMs: CORE STRENGTHS OF MEDBEN RX OVER TRADITIONAL MODELS True Transparency & Pass-Through Traditional PBMs frequently use “spread...
May 26, 2026 | Benefits preservation, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
A recent Pharmaceutical Strategies Group analysis shows managing specialty drug costs is now the top priority for employer health plans —surpassing total cost of care. MedBen Rx’s Benefit Preservation Program addresses this by reducing specialty drug spend by an...
May 4, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rebates, Rx Costs, Savings
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the effect is already clear, with...
Mar 23, 2026 | Clinical guidelines, Drug advertising, MedBen Rx, Rx Costs
Heavy direct-to-consumer advertising of high-cost medications is fueling patient demand and placing added pressure on physicians to prescribe the drugs that patients recognize — even when lower-cost alternatives may be just as, or more, effective. The scale of this...
Feb 23, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Jan 12, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance, Pharmacogenomics, Pharmacy
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
